Live

Watch: A Yahoo Finance special report on Apple's earnings

OTC Markets OTCQB USD

ZIVO Bioscience, Inc. (ZIVO)

18.80

0.00

(0.00%)

At close: April 30 at 4:00:00 PM EDT

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

TROY, Mich., February 06, 2025--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces plans for a second collaborative study with the University of Delaware. This new study aims to further explore the potential applications of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus amon

Business Wire 2 months ago

ZIVO
0.00%

ZIVOW
ZIVO Bioscience to Present at The Microcap Conference 2025

BLOOMFIELD HILLS, Mich., January 22, 2025--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.

Business Wire 3 months ago

ZIVO
0.00%

ZIVOW
ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities

BLOOMFIELD HILLS, Mich., December 23, 2024--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on activities related to licensing its product targeting coccidiosis in broiler chickens.

Business Wire 4 months ago

ZIVO
0.00%

ZIVOW
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

BLOOMFIELD HILLS, Mich., December 20, 2024--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO’s proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poult

Business Wire 4 months ago

ZIVO
0.00%

ZIVOW
Director and 10% Owner Christopher Maggiore Acquires 31,336 Shares of Zivo Bioscience Inc (ZIVO)

On August 22, 2024, Christopher Maggiore, serving as Director and 10% Owner, purchased 31,336 shares of Zivo Bioscience Inc (ZIVO) as reported in a recent SEC Filing. Zivo Bioscience Inc is engaged in the study, development, and commercialization of natural bioactive compounds derived from its proprietary algal cultures to address dietary and health-related markets. The transaction occurred when shares of Zivo Bioscience Inc were priced at $8.34, resulting in a total investment by the insider of approximately $261,043.44.

GuruFocus.com 8 months ago

ZIVOW
ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens

BLOOMFIELD HILLS, Mich., August 23, 2024--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens.

Business Wire 8 months ago

ZIVO
0.00%

ZIVOW
Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience’s Coccidiosis Treatment in Broiler Chickens

BLOOMFIELD HILLS, Mich., July 08, 2024--ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day confirmatory study targeting coccidiosis in collaboration with a major global animal health company.

Business Wire 9 months ago

ZIVO
0.00%

ZIVOW

Performance Overview

Return	ZIVO	S&P 500 (^GSPC)
YTD	-12.56%	-4.72%
1-Year	+137.97%	+11.67%
3-Year	-2.08%	+35.63%

Try again.